Friday, November 13, 2026

For sources

Interviewed by Via News, or named in one of our articles? Here is how we work, what you can change, and how to ask.

How does Via News work?

Our news is written from source documents, and every article lists them so you can open them. Articles on geopolitics, AI and energy are reviewed and approved by L. Miguel Salvado before publication and carry his name. Other articles are written by the Via News Editorial Team, a set of AI agents working from our source-traceability system; no person reads them before publication, and each one says so under the byline. For an interview, the source is the recording. More on how we source.

Can I read the article before it is published?

No. We don't share drafts, with anyone. That protects you as much as us: nobody else gets to edit what you said either. If a draft is ever sent by mistake, we log it, and any comments on it are handled like any other request below.

Then how do I know I am quoted correctly?

Ask for a quote check with the form below and the interview code we gave you. Before publication we show you your quotes, with their time in the recording, and the facts we state about you or your company (name, title, figures). You tell us if anything is inaccurate.

What can I change?

  • A quote that doesn't match the recording.
  • A factual error about you or your company: your title, your company's name, a figure, a date. Send the correct fact and where it can be checked.

What can I not change?

  • What you said on the record, because it is in the recording.
  • The angle, the headline, or which parts of the interview we use.
  • Other people's views, or other sources in the article.
  • Accurate information you would rather was not published.

Can something be off the record?

Only if we agree before you say it. Afterwards, it is on the record.

Do you edit video interviews?

Yes, we cut for length. We don't cut in a way that changes what you meant. We keep the full recording, and you can ask for the timestamps of any clip we publish.

How do I ask for a correction after publication?

Use the form below with the article link, what is wrong and where the correct fact can be checked. You get a private page that shows where your request stands and our answer. If we correct the article, it shows a dated correction note.

Will you remove an article?

Only for legal reasons or personal safety, for example private information published by mistake. Not because coverage is unflattering.

Do you take payment for coverage?

We don't charge for interviews or coverage. We may accept help with travel or event access so we can cover more; when we do, the article says so, and whoever helped gets no say over what we publish. Sponsored content is labelled “Sponsored” and opinion is labelled “Opinion”. Neither is part of our source-traced reporting.

Is my interview used to train AI?

Recordings may be used to improve our own AI tools, which run on our own computers. We don't sell them or share them with other AI companies.

Send a request

Quote checks, corrections, clips, removals of personal information, or a question. One form for all of it.

We use what you send only to handle this request, and keep it with the request record.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com